Latest Forum Topics /
IX Biopharma
Last:0.355
+0.01
|
 Post Reply
|
|
iX Biopharma
|
|||||
|
spursfan
Supreme |
11-Feb-2022 14:47
|
||||
|
x 0
x 0 Alert Admin |
let wait a while. ED drugs need time to take effect. hahaha | ||||
| Useful To Me Not Useful To Me | |||||
|
jack_ng
Member |
11-Feb-2022 14:37
|
||||
|
x 0
x 0 Alert Admin |
Patience with a capital P
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Stocksguru
Master |
11-Feb-2022 14:34
|
||||
|
x 0
x 0 Alert Admin |
B4 Covid loss money 20x now earn money also 20x LOL look like this stock need some of their medication for the ED
|
||||
| Useful To Me Not Useful To Me | |||||
|
jack_ng
Member |
11-Feb-2022 14:27
|
||||
|
x 0
x 0 Alert Admin |
Hope that the profit will make IX the turnaround stock of 2022 Holding tight |
||||
| Useful To Me Not Useful To Me | |||||
|
Stocksguru
Master |
11-Feb-2022 14:10
|
||||
|
x 0
x 0 Alert Admin |
they do medical for ED seen like their stock should also do the same can shoot up.
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
AnthonyWoodPeck
Member |
11-Feb-2022 14:04
|
||||
|
x 0
x 0 Alert Admin |
IX Bio hope can surprise us this time | ||||
| Useful To Me Not Useful To Me | |||||
|
Stocksguru
Master |
11-Feb-2022 13:54
|
||||
|
x 0
x 0 Alert Admin |
They do medicine for KKJ? | ||||
| Useful To Me Not Useful To Me | |||||
|
spursfan
Supreme |
11-Feb-2022 13:41
|
||||
|
x 0
x 0 Alert Admin |
i thought it is going to be fast n furious. hahaha | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
piscesmonkey
Supreme |
11-Feb-2022 13:37
|
||||
|
x 0
x 0 Alert Admin |
Hmm so many selling? Bought around 0.190? | ||||
| Useful To Me Not Useful To Me | |||||
|
spursfan
Supreme |
11-Feb-2022 13:25
|
||||
|
x 0
x 0 Alert Admin |
trading starting soon | ||||
| Useful To Me Not Useful To Me | |||||
|
spursfan
Supreme |
11-Feb-2022 13:12
|
||||
|
x 0
x 0 Alert Admin |
temp. halt to allow 30min. dissemination time following release of results
|
||||
| Useful To Me Not Useful To Me | |||||
|
Stocksguru
Master |
11-Feb-2022 13:04
|
||||
|
x 0
x 0 Alert Admin |
Yesterday think of going in but chose ipx secura .... | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
piscesmonkey
Supreme |
11-Feb-2022 13:00
|
||||
|
x 0
x 0 Alert Admin |
Wow halt liao | ||||
| Useful To Me Not Useful To Me | |||||
|
piscesmonkey
Supreme |
11-Feb-2022 12:58
|
||||
|
x 0
x 0 Alert Admin |
SuperB result.
|
||||
| Useful To Me Not Useful To Me | |||||
|
spursfan
Supreme |
11-Feb-2022 12:57
|
||||
|
x 0
x 0 Alert Admin |
iX Biopharma Records 1H22 Net Profit of S$3.66M &bull Revenue lifted to S$13.19M v 1H21 of S$0.83M, driven by Wafermine outlicensing contribution &bull Strong balance sheet with cash balance of S$16.69M, another upfront fee payment of S$1.58M received in Jan 2022 https://links.sgx.com/1.0.0/corporate-announcements/M3RMLRGJR0R9X85O/701761_Press%20Release%20-%20iX%20Biopharma%20Records%201H22%20Net%20Profit%203.66M%20final.pdf |
||||
| Useful To Me Not Useful To Me | |||||
|
piscesmonkey
Supreme |
11-Feb-2022 12:55
|
||||
|
x 0
x 0 Alert Admin |
WOW after so long start have profit liaoz huat ah | ||||
| Useful To Me Not Useful To Me | |||||
|
Smartbet
Member |
28-Jan-2022 16:46
|
||||
|
x 0
x 0 Alert Admin |
I am just waiting to exit when I break even. No patience waiting for this joker stock that keep trending lower despite being in a better position than before. Hard to justify.
|
||||
| Useful To Me Not Useful To Me | |||||
|
Observers
Elite |
10-Jan-2022 09:06
|
||||
|
x 0
x 0 Alert Admin |
Ever considered investing in this counter but scare kenna karma? Then again not everyone believes in it? Specific to the deal, personally I' m wary of JVs with partners that don' t have enough capital and have to use their shares to make up the shortfall? | ||||
| Useful To Me Not Useful To Me | |||||
|
ahberngh
Elite |
10-Jan-2022 08:31
|
||||
|
x 0
x 0 Alert Admin |
Now to aggressively market all their other products, NAD+, xativa, Wafesil, etc. | ||||
| Useful To Me Not Useful To Me | |||||
|
spursfan
Supreme |
10-Jan-2022 08:11
|
||||
|
x 0
x 0 Alert Admin |
WAFERMINE LICENSING TRANSACTION &ndash RECEIPT OF UPFRONT PAYMENT The board of directors (&ldquo Board&rdquo ) of iX Biopharma Ltd (the " Company" ) refers to the Company&rsquo s announcement dated 24 November 2021 (the &ldquo Announcement&rdquo ) relating to the Exclusive License Agreement for Wafermine and other products incorporating R- and S- enantiomers of ketamine utilizing the WaferiX technology (the &ldquo License Agreement&rdquo ). Unless otherwise defined, all capitalised terms herein shall have the same meanings as in the Announcement. The Board is pleased to inform shareholders that the Company has received, as consideration for the license under the License Agreement, an upfront fee of US$9,000,000 comprised of: (a) US$3,500,000 in cash (b) 2,570,266 shares in Seelos (the &ldquo Upfront Shares&rdquo ) and (c) US$1,173,728 in additional cash (the &ldquo Additional Cash&rdquo ) as reimbursement of the Shortfall Amount (as defined below). The Upfront Shares were issued by Seelos and have been registered on 27 December 2021 with the Securities and Exchange Commission (&ldquo SEC&rdquo ) pursuant to a Common Stock Purchase Agreement dated 24 November 2021 entered into between the parties (the &ldquo Stock Agreement&rdquo ). Following the registration of the Upfront Shares, the Company is entitled to sell the Upfront Shares without restriction. The Additional Cash was paid as reimbursement to the Company by Seelos for the difference in value (the &ldquo Shortfall Amount&rdquo ) in the event that the aggregate value of the Upfront Shares is less than $5,500,000 when calculated in accordance with the Stock Agreement. Under the Stock Agreement, the value of one share will be equal to the volume weighted average closing price of Seelos&rsquo shares, as reported on Nasdaq for the ten consecutive trading days ending on the third trading date prior to the effective date of the registration statement filed by Seelos with the SEC, being 27 December 2021. In addition to the above payments, the Company will be paid up to US$239 million in development, regulatory and commercial milestones and double digit percentage royalty payments as further set out in the License Agreement. The Board will make further announcements on any further material payments received as and when appropriate. BY ORDER OF THE BOARD https://links.sgx.com/1.0.0/corporate-announcements/4GGY92TVA3NGQIFQ/697076_iX%20Biopharma-Wafermine%20licensing-Receipt%20of%20payment.pdf |
||||
| Useful To Me Not Useful To Me | |||||